Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (August 2020)

41 slides from Windtree Therapeutics's investor presentation, Aug 20, 2020

  1. Slide 1: Company Overview

    Windtree Therapeutics wy Company Overview “@ 20, 2020 WINDTREE THERAPEUTICS

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company

  3. Slide 3: Windtree Therapeutics

    Windtree Therapeutics Windtree Therapeuticsis a clinical-stage biopharmaceutical and medical device company with multiple advanced clinical programs spanning cardiovascular and respiratory disease states PI Lead Products se! | Phase ll | Phase Ill |Next stone FDA ost Track Istaroxime * Initiate stud

  4. Slide 4: Strategy for Value Creation

    Strategy for Value Creation Planned Milestones * Three clinical programs focused on significant markets with unmet needs = Multiple clinical and business milestones which have the potential to be catalysts | Qu a2 a3 a4 ai a2 a3 Qa Istaroxime Early Cardiogenic ShockStudy ____ spanig = tstaroxime. ‘A

  5. Slide 5: Istaroxime

    Istaroxime Dual Mechanism, SERCA2a Activator for the Treatment of Acute Heart Failure and Early Cardiogenic Shock

  6. Slide 6: Heart Failure

    Heart Failure - The prevalence of HF is high and on the rise (as is mortality) # of Patients: 6M (U.S.) | 18M (Worldwide) Hospital Admissions: #1 cause of hospitalization in patients > 65 years old (U.S.) > 1.3M admissions annually (U.S.) ~1.5M admissions annually (E.U.) Inpatient Mortality: Up to 7

  7. Slide 7: Acute Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need

    Acute Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need * There has not been meaningful new pharmacologic advancements in acute heart failure for decades = Current approaches to acutely improve cardiac function are associated with unwanted effects: Heart rhythm distur

  8. Slide 8: Istaroxime — Novel First-in-Class Therapy

    Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart. 2 Inhibition of the sodium- : ‘Stimulation of SERCA2a activity enhances potassium pump and effects on calcium reuptake resulting in the sodium-calcium exc

  9. Slide 9: Istaroxime AHF Phase 2b Study - Summary

    Istaroxime AHF Phase 2b Study - Summary Primary = Change in E/e’ at 24 hours (non-invasive estimate of PCWP) measured by Endpoint: echocardiography Trial Design: = Adult patients hospitalized for recurrent AHF (dyspnea plus need for lV furosemide 2 40mg) = 120 patients = Multicenter, double blind, p

  10. Slide 10: Primary Endpoint — Significant Changes in E/e' Ratio and Stroke Volume

    Primary Endpoint — Significant Changes in E/e' Ratio and Stoke Volume istaroxime0.5 g/kg/min vs. placebo Efe natio 20 10 00 10 20 30 40 50 60 Infusion period * 20 * pyvalue = 0.029 Beene Shouse 2s hows “a8 hous m-e= Plcebo-Cohort 1 agemisarcximeos uelta/min istaroxime 1.0 ug/kg/min vs. placebo eo °°

  11. Slide 11: Systolic Blood Pressure Maintained or Increased During Treatment and Renal Function Tended to Improve

    Systolic Blood Pressure Maintained or Increased During Treatment and Renal Function Tended to Improve istaroxime 0.5 yg/kg/min vs. placebo istaroxime 1.0 y.g/kg/min vs. placebo t i A SBP é Wa 6 | Tifaston pened | jt pvalues0.u, ** pales s.008 RE ORR ara, Se RRR GFR GFR ml/min), GFR (min amet | 8 ap

  12. Slide 12: Istaroxime — Acute Heart Failure Next Steps

    Istaroxime — Acute Heart Failure Next Steps Objective: Create a strong phase 3 and partnership position - * Execute an additional study that is expected to complete Phase 2 and inform Phase 3 - 300 patients, 75 centers globally (estimates) + Leverage characteristics in a target population that most

  13. Slide 13: Early Cardiogenic Shock Treatment

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Approval Pathway Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output No Satisfactory Pharmacologic

  14. Slide 14: Istaroxime SBP Change from Baseline Phase 2a and 2b Dose Groups

    Istaroxime SBP Change from Baseline to 6 or 24 Hours fr Phase 2a and 2b Dose Groups Istaroxime has the potential to improve blood pressure and organ perfusion in patients with AHF 20.0 18.0 16.0 14.0 12.0 10.0 8.0 6.0 4.0 2.0 0.0 2a Study 2b Study 2a Study 2b Study 2a Study SBP Mean Change + SE (mmH

  15. Slide 15: Istaroxime — Early Cardiogenic Shock — Next Steps

    Istaroxime — Early Cardiogenic Shock — Next Steps + Initiate a study in early cardiogenic shock while we are preparing for the larger phase 2b acute heart failure study - ~60 patients conducted in the Europe and US - Start Q3-2020with data expected in mid-2021 + Phase 2 clinical program suggests a m

  16. Slide 16: Pre-Clinical Programs

    Pre-Clinical Programs Novel Oral SERCA2a Activators for HF + Acute Pulmonary Platform The Companyalso has early exploratory research programs to identify potential product candidatesincluding: Cardiovascular Selective SERCA2a Dual Mechanism Compounds Activators for Heart Failure * Oral &i.v. therapi

  17. Slide 17: COVID-19 Lung Injury Treatment

    E COVID-19 , Lung Injury Treatment Synthetic KL4 Surfactant for the Treatment of Lung Injury in COVID-19 Patients

  18. Slide 18: COVID-19 and ARDS Have A Significant Negative Impact On Surfactant Related Lung Function

    COVID-19 and ARDS Have A Significant Negative Impact On Surfactant Related Lung Function Uses angiosten- [ACE isa surface molecule on Damaged Type 2 cells Increased likelihood of converting enzyme 2. _ alveolar Type 2 cells of lungs, results in impaired mechanical ventilation (ACE2)for entry into _‘

  19. Slide 19: KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical H5N1 Study

    KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical H5N1 Study — With and Without Anti-Viral Agent = Ferrets Infected with highly pathogenic avian (H5N1) influenza ® Results in significant viral and inflammation related lung damage that is substantially ameliorated by KL4 surfactant tre

  20. Slide 20: Surfactant Administration In Severe COVID-19 Lung Injury

    Surfactant Administration In Severe COVID-19 Lung Injury May Have Potential to Provide Significant Benefits " We believe our synthetic KL4 surfactant may have the potential to mitigate surfactant deficiency and resist the 8 widespread surfactant destruction that can occur asa BY result of COVID-19 =

  21. Slide 21: Clinical Proposal: Lucinactant (KL4 Surfactant) For The Treatment of COVID-19

    Clinical Proposal: Lucinactant (KL4 Surfactant) For The Treatment of COVID-19 Initial phase 2 study will be to demonstrate changes in physiological parameters in COVID-19 associated lung injury and ARDS ¢ Up to 20 patients from 4-5 US sites (lead by institutions in Boston & Durham, NC) © Dosing thro

  22. Slide 22: Evidence of KL4 Surfactant Potential Utility in COVID-19

    Evidence of KL4 Surfactant Potential Utility in COVID-19 — Demonstrated Utility Across Various Respiratory Distress Demonstrated Utility of KL4 Extensive Studies in. "13 studies for intratracheal administration including RDS, BPD, acute ‘Acute Lung Conditions: _-hypoxemic respiratory failure and adu

  23. Slide 23: AEROSURF

    AEROSURF*® Synthetic KL4 Surfactant with Proprietary Aerosol Delivery System for the Treatment of RDS

  24. Slide 24: Respiratory Distress Syndrome (RDS) Current Treatment Pathways

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways = Premature infants experience respiratory distress syndrome (“RDS”) due to lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and gas exchange = Physicians have to choose between invasive surfactant de

  25. Slide 25: AEROSURF - Potential to Impact the Clinical Course of RDS

    AEROSURF® - Potential to Impact the Clinical Course of RDS Building Evidence From Nearly 400 Patients Studied Noninvasive RDS treatment Improved Long-Term Respiratory Outcomes Study results across each Parameters of these important parameters show evidence of a potential impact on the clinical cours

  26. Slide 26: AEROSURF Program Evolution and Strategy

    AEROSURF® Program Evolution and Strategy Mitigating Risks and Strengthening Our Approach Program Evolution Completed three phase 2a and 2b trials Execute a small (n=~80 - 90) Bridging Study to transition to EOP2 / Phase 3 Efficacy in reducing nCPAP failure and the need for intubation = = P Demonstra

  27. Slide 27: Summary

    Summary

  28. Slide 28: Business Development Focus

    Business Development Focus We are actively engaged in discussions with multiple companies with a proactive focus as follows: Cardiovascular Partner — China Pure SERCA2a Pharma Partner — Global AEROSURF® / KL4 — Project Financing Model Heart Failure Portfolio Partner — Global Mid-term Rosta Out-Licen

  29. Slide 29: Financial Summary & Capitalization as of June 30, 2020

    Financial Summary & Capitalization as of June 30, 2020 = Cash & Equivalents of $31.5 million = Debt: ~$2.4M bank credit facility as of August 13, 2020 due in March 2022 Common Equivalents Secut Ss Common Stock 16,868,732 Options (WAEP $17.41) 1,761,949 RSUs 35,000 Warrants (WAEP $16.38) 7,913,900 Fu

  30. Slide 30: Multiple Development and Business Activities Create a Robust Outlook of Potential Milestones

    Multiple Development and Business Activities Create a Robust Outlook of Potential Milestones 2020 / 1H 2021 Planned Events Strategy for Value Creation * AEROSURF bridge study start, Planned Malestones | and final data + Nasdaq Listing (and raise) * — Istaroxime Cardiogenic Shock study start, datarea

  31. Slide 31: Windtree Therapeutics

    Windtree Therapeutics “Striving to deliver Hope for a Lifetime!” SQ winotree a6

  32. Slide 32: Appendix

    Appendix 88 WINDTREE we"

  33. Slide 33: Cardiac Output, Blood Pressure and Renal Function are Critical Factors in Managing AHF

    Cardiac Output, Blood Pressure and Renal Function are Critical Factors in Managing AHF Patients and Their Outcomes Early drop in systolic blood pressure ‘and worsening renal function in acute heart In-Hospital Mortality Rates by Admission upper vegier Meenas am Systolic Blood Pressure Deciles (n = 4

  34. Slide 34: Istaroxime Phase 2a (HORIZON-HF) Study

    Istaroxime Phase 2a (HORIZON-HF) Study = Multicenter, double blind, placebo-controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU = Hospitalized with AHF, with criteria including: © LVEF < 35% * SBP 90-150 mmHg = N=120 (30/group) = Significant improvement in PC

  35. Slide 35: Istaroxime Phase 2b Study

    Istaroxime Phase 2b Study Favorable Profile Observed with 24-hour Holter Monitoring Glinically significant arrhythmias Clinically significant arrhythmias 120% — 105% 1058 105% 100% 250% 00% 20.0% ae ra0% oN wae I .o% I o% 40% MH 3% 1 aM 1 atid 20% som am ox emeine —eyA(ison) ey? seine it om? ePlecco

  36. Slide 36: Istaroxime Phase 2b Adverse Events

    Istaroxime Phase 2b Adverse Events Istaroxime 0.5 istaroxime 1.0 con ca main popaae (n=41) ) All adverse events, 23 (59.0%) 31 (75.6%) 33 (82.5%) ‘Adverse events leading to pablo 1 (2.6%) : 4 (10.0%) Serious adverse events 2 (5.1%) 2 (4.9%) 6 (15.0%) Cardiac death : - 1 (2.5%) Cardiogenic shock = z

  37. Slide 37: Respiratory Distress Syndrome (RDS) Current Treatment Pathways

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways Premature infants experience RDS due to underdeveloped lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and proper gas exchange Initial treatment options include invasive and noninvasive methods: Surf

  38. Slide 38: Windtree Technology Platform - AEROSURF

    Windtree Technology Platform - AEROSURF® Proprietary Synthetic KL4 Surfactant Structurally similar to human lung surfactant Utilizing pressure and heated capillary has demonstrated Liquid KLs surfactant (intratracheal instillate) ablifty 10 anronolien Ka surface for RDS approved by the FDA lyophiliz

  39. Slide 39: Transformative Potential of AEROSURF

    Transformative Potential of AEROSURF® RISKS Reyorsing surfactant deficiency. has ‘ profound positive impact on respiration Surfactant therapy delivers near-immediate clinical improvement BPD Infection, ventilator-induced pneumoni cord damage, asthma, lung damage nCPAP Respiratory Support a tothe ris

  40. Slide 40: References Supporting Utilization of KL4 Surfactant for the Treatment of Lung Injury

    References Supporting Utilization of KL, Surfactant for the Treatment of Lung Injury 21. &, oftmann, MH. Kleine Weber, etal 2020), "Thenovelcoronavitss2019(2019-nCoV) usestheSARScorcnavirusreceptor ACE2 andtheceluar protease TMPRSS2for entero ‘target ceis10. 1201/2020 01 31.928082" pif: 2020.01 3.92

  41. Slide 41: Surfactant in ARDS References

    Surfactant in ARDS References 1. Gregory 1, Steinberg KP, Sprage R, Gadek J, Hyers TM, Longmore Wi etal. Bovine surfactanttherapy for patients with acute respiratory distresssyndrome. Aan J Respir ritCare Med, 1997;155:1308-1515, 2. Wiedemann H, Saughman 8 de BoisblancE,et al, A mult centered tral i

Windtree Therapeutics — Investor Presentation (August 2020) on 6ix